Landos’ second first-in-class product candidate designed to provide a safer and more convenient treatment for ulcerative colitis patients Topline results are expected in the first quarter of 2022 ...
BLACKSBURG, Va., April 29, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results